Hints and tips:
...He also has served on the board of Genzyme, the biotech company sold to Sanofi-Aventis this year for more than $20bn....
...The head of Sanofi-Aventis on Wednesday predicted more use of conditional payments in future biotech takeovers, as he clinched the $20bn purchase of US biotech company Genzyme with a promise of up to $14...
...Genzyme, the US biotech company, has signed a non-disclosure agreement with Sanofi-Aventis as it steps up talks over a proposed $18.5bn takeover by the French pharmaceutical group, reports the FT....
...Sanofi-Aventis is set to raise its bid for Genzyme to more than $20bn to clinch an agreed takeover of the US biotech business after months of disagreement, reports the FT....
...Sanofi-Aventis is poised to raise its cash offer for Genzyme, as it pushes to seal its takeover bid for the US biotech company ahead of Sanofi’s full-year results this week, reports the FT....
...News came on Wednesday morning that Sanofi-Aventis has finally clinched its deal to buy Genzyme after raising its offer to $20.1bn for the US biotech business....
...In a research note on Monday, Cowen argued that a number of the large pharmaceutical groups, led by Eli Lilly, Sanofi-Aventis and Pfizer, would be worth more if they divested separable business units, which...
...French drugmaker Sanofi-Aventis said on Monday it had called on bid target Genzyme to let shareholders of the US biotech company decide on Sanofi’s $18.5bn offer, reports Reuters....
...Sanofi-Aventis has continued aggressively to acquire others, including ultimately winning support for the takeover of US group Genzyme after raising its bid above $20bn....
...Sanofi-Aventis has launched a hostile $18.5bn takeover of Genzyme, criticising what it claimed was the US biotech company’s inability to overcome manufacturing problems or launch new products on its own,...
...Henri Termeer, chairman and CEO of the US biotech, reiterated the board’s rejection in late July of Sanofi’s $18.5bn cash offer....
...Diabetes medications still make up about 17 per cent of Lilly’s $22bn revenues, but in recent years it has lost ground to rivals such as Merck and Sanofi-Aventis....
...Sanofi-Aventis stepped up its pursuit of Genzyme on Sunday, outlining publicly its interest in a takeover deal as it edged towards a hostile bid for the US biotech company, reports the FT....
...Genzyme’s chief executive on Monday said he was open to selling the US biotech company at a “fair value” but that the $69-a-share offer from French group Sanofi- Aventis was not enough, reports Bloomberg...
...Genzyme, a US biotech company, is weighing an informal takeover approach from France’s Sanofi-Aventis but is not looking to sell the company, Reuters reports, citing a source close to the situation....
...Sanofi-Aventis of France is set to proceed with a formal offer for Genzyme that could value the US biotech company at close to $19bn, reports the FT....
...Sanofi-Aventis of France has sent a takeover proposal valued at about $18.4bn or $69 per share, to US biotech company Genzyme and the two sides are discussing the offer, reports Reuters on Monday....
...Sanofi-Aventis stepped up its pursuit of Genzyme on Sunday, outlining publicly its interest in a takeover deal as it inched closer to making a hostile offer for the US biotech company....
...High factory automation has helped contain V-Zug’s costs, including a smart new computerised logistics centre opened this year. “Productivity is a key success factor for us,” Mr Buhofer says....
...- Sanofi plots $16bn buy of Genzyme. - British Gas to double profits. - LibDems propose reviving local exchanges. From the Sunday Telegraph, - BP’s Tony Hayward will ‘quit in days....
...Sanofi-Aventis, the French pharmaceuticals group, has agreed to buy Chattem, a US consumer healthcare company, in a $1.9bn cash deal that will hasten its diversification away from prescription medicines....
...The IPO price was the highest by any company in China, helping Hepalink raise 5.9bn yuan ($864m) to expand production capacity to supply clients including Paris-based Sanofi-Aventis SA....
...In pharmaceuticals, the government engineered the merger between Sanofi and Aventis to create a new champion rather than allow the Swiss Novartis to swallow it up....
...Deal making is heating up in the world of big pharma, with French drugs group Sanofi-Aventis on Thursday confirming that it is paying Merck $4bn to take control of their animal health joint venture Merial...
...With the almost certain return of growth in the previous quarter, it is not an “L” but not yet robust enough to be a “V”. The likelihood of a “W” also seems far-fetched....
International Edition